Table 3. Hormonal therapy response of recurrent low-grade serous ovarian carcinoma by hormonal agent and platinum sensitivity status.
| Regimen | CR | PR | SD | PD | Total | ||||
|---|---|---|---|---|---|---|---|---|---|
|
| |||||||||
| PSe | PRe | PSe | PRe | PSe | PRe | PSe | PRe | ||
| Anastrozole | 1 | 0 | 0 | 0 | 9 | 5 | 2 | 4 | 21 |
| Fulvestrant | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 2 |
| Letrozole | 3 | 1 | 2 | 0 | 9 | 8 | 4 | 6 | 33 |
| Leuprolide | 0 | 0 | 0 | 0 | 5 | 1 | 1 | 1 | 8 |
| Megestrol acetate | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Tamoxifen | 1 | 0 | 0 | 0 | 8 | 3 | 1 | 4 | 17 |
| Raloxifene | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
| Anastrozole + leuprolide | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
| Letrozole + leuprolide | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 3 |
| Tamoxifen + leuprolide | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 2 |
|
| |||||||||
| Total | 5 | 1 | 2 | 0 | 36 | 19 | 9 | 17 | 89 |
CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease ; PSe, platinum-sensitive; PRe, platinum-resistant